Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Gifu University and Astellas establish a Research Course on Phage Biologics, aimed at creating new treatments for bacterial infections

03/18/2020 | 07:09am EST

TOKYO - Gifu University (President: Hisataka Moriwaki M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that the parties have established, inside Gifu University Graduate School of Medicine, a joint research course entitled, 'Phage Biologics Research Course' (Lead professor: Hiroki Nagai, Ph.D., Professor of Microbiology, Gifu University Graduate School of Medicine; Lead researcher: Hiroki Ando, Ph.D., Principal Investigator1 of Astellas is on loan to Gifu University as project associate professor).

In the Phage Biologics Research Course, Gifu University and Astellas will conduct a joint study on bacterial infection treatment by using engineered bacteriophages2. The course will be retained for a term of three years from March 2020.

Phage therapy is known for being a treatment that aims to selectively eliminate bacteria from the living body by using bactericidal actions, the primary properties of a virus, and taking advantage of the characteristic of viruses in the natural world that specifically infect target bacteria. Due to the advancement of genetic engineering technology, progress is being made in recent years in the research of enhancing the usefullness and safety of engineered bacteriophage. It is attracting attention as the next-generation phage therapy technology. This technology is expected to be useful not only for the treatment of common bacterial infections, but also for the new treatment of difficult-to-treat bacterial infections and for solving the problem of antimicrobial resistance (AMR) 3, a serious global threat to public health.

Gifu University Graduate School of Medicine has been engaged for some time in the research of engineered bacteriophages applicable to next-generation phage therapy. Through this joint research, while making use of the strength of academia in which knowledge gained from clinical practice can be inputted, Gifu University will work to create engineered bacteriophages against multiple target bacteria through an industry-academia collaboration with Astellas.

The VISION of Astellas is 'On the forefront of healthcare change, turning innovative science into value for patients.' Along with in-house R&D, collaborations and partnerships play an important role in realizing this VISION. Astellas actively explores and evaluates collaboration opportunities that match the company's innovations and business strategies. The establishing of this joint research course is part of this effort.

Through this joint research, Gifu University and Astellas will take on the challenge of creating multiple lead programs in the field of bacterial infection treatment that uses engineered bacteriophages, to further bring benefit to patients.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Astellas Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contact:

Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ASTELLAS PHARMA INC.
01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
AQ
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
AQ
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
MT
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
AQ
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
AQ
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
AQ
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
AQ
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
RE
2020Japanese shares slip back as investors look to U.S. stimulus debate
RE
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
MT
More news
Financials
Sales 2021 1 272 B 12 253 M 12 253 M
Net income 2021 181 B 1 744 M 1 744 M
Net cash 2021 440 B 4 239 M 4 239 M
P/E ratio 2021 17,0x
Yield 2021 2,50%
Capitalization 3 130 B 30 155 M 30 153 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,93x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 685,00 JPY
Spread / Highest target 114%
Spread / Average Target 34,6%
Spread / Lowest Target -2,08%
EPS Revisions
Managers and Directors
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.5.71%30 155
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159